Raymond James Trust N.A. grew its holdings in shares of Celgene Corporation (NASDAQ:CELG) by 21.5% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 30,132 shares of the biopharmaceutical company’s stock after buying an additional 5,329 shares during the period. Raymond James Trust N.A.’s holdings in Celgene Corporation were worth $3,913,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of CELG. Capital Counsel LLC NY boosted its position in shares of Celgene Corporation by 0.4% during the second quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock valued at $214,000 after purchasing an additional 6 shares in the last quarter. Sowell Financial Services LLC boosted its position in shares of Celgene Corporation by 0.5% during the first quarter. Sowell Financial Services LLC now owns 2,454 shares of the biopharmaceutical company’s stock valued at $289,000 after purchasing an additional 13 shares in the last quarter. South Texas Money Management Ltd. boosted its position in shares of Celgene Corporation by 0.6% during the first quarter. South Texas Money Management Ltd. now owns 2,453 shares of the biopharmaceutical company’s stock valued at $305,000 after purchasing an additional 15 shares in the last quarter. Flagship Harbor Advisors LLC boosted its position in shares of Celgene Corporation by 0.9% during the first quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock valued at $253,000 after purchasing an additional 18 shares in the last quarter. Finally, Savant Capital LLC boosted its position in shares of Celgene Corporation by 0.9% during the second quarter. Savant Capital LLC now owns 2,350 shares of the biopharmaceutical company’s stock valued at $305,000 after purchasing an additional 20 shares in the last quarter. 79.16% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Celgene Corporation (NASDAQ:CELG) opened at $103.35 on Friday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. Celgene Corporation has a 1 year low of $94.55 and a 1 year high of $147.17. The stock has a market capitalization of $78,999.38, a PE ratio of 15.68, a P/E/G ratio of 0.77 and a beta of 1.79.

Celgene Corporation (NASDAQ:CELG) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.04. Celgene Corporation had a return on equity of 63.80% and a net margin of 27.36%. The firm had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. During the same quarter last year, the business posted $1.58 earnings per share. The firm’s revenue was up 10.2% on a year-over-year basis. analysts forecast that Celgene Corporation will post 6.67 EPS for the current fiscal year.

CELG has been the topic of several research reports. Cann restated a “buy” rating and set a $175.00 price target on shares of Celgene Corporation in a research report on Tuesday, August 1st. Jefferies Group LLC reissued a “buy” rating and issued a $160.00 target price on shares of Celgene Corporation in a report on Monday, July 31st. Cantor Fitzgerald set a $160.00 target price on Celgene Corporation and gave the stock a “buy” rating in a report on Thursday, July 27th. Mizuho set a $134.00 target price on Celgene Corporation and gave the stock a “buy” rating in a report on Wednesday, July 26th. Finally, Canaccord Genuity set a $156.00 target price on Celgene Corporation and gave the stock a “buy” rating in a report on Thursday, July 27th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $139.64.

ILLEGAL ACTIVITY WARNING: “Celgene Corporation (CELG) Shares Bought by Raymond James Trust N.A.” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.watchlistnews.com/celgene-corporation-celg-shares-bought-by-raymond-james-trust-n-a/1708675.html.

In related news, Director Gilla Kaplan sold 9,250 shares of the stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the completion of the sale, the director now owns 85,551 shares in the company, valued at $12,110,599.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Terrie Curran sold 1,727 shares of the stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the sale, the insider now owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The disclosure for this sale can be found here. Insiders have sold 20,227 shares of company stock valued at $2,843,956 in the last quarter. 0.95% of the stock is currently owned by company insiders.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.